Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

Contrary to some commonly held beliefs, current research shows that cutting out certain foods makes little difference in ...

Prenatal exposure to fine particulate matter (PM2.5) at levels above 65 µg/m³ was associated with a sharp rise in atopic ...

Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped ...

Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

Term Maintenance and Durability THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...

Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) ...

Amid limited access to pediatric dermatologists nationwide, pediatric patients of color with atopic dermatitis (AD) are ...

A break from treatment with Vtama won’t lead to worsening of patients’ atopic dermatitis, finds a new analysis of an ...

Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.